Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7794044 | 1.00 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL24016961 | 1.00 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL2478210 | 0.98 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL30514621 | 0.94 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL7794525 | 0.93 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL171236 | 0.89 | POLB (0.47) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL11526941 | 0.89 | MAPT (0.61) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL3400048 | 0.89 | MAPT (0.61) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL78145 | 0.89 | MAPT (0.61) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL11526739 | 0.86 | MAPT (0.63) | RAB9ANPC1SMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047058-A | N, N- dimethyl -4- cyclohexylamino cyclohexyl-methanes and its preparation method and application | 万华化学集团股份有限公司 | 2018-05-18 | — | — | CN | claimed |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3912974-A1 | TRIAZOLE COMPOUNDS, AND PREPARATION METHOD THEREOF AND USE | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3326715-B1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | CE PHARM CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3078658-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-108774237-A | New tricyclic compound | ABBVIE 公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-104370909-B | Tricyclic compound | ABBVIE 公司 | 2018-09-11 | — | — | CN | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007078134-A1 | TRANSITION METAL COMPLEXES AND PREPARATION METHODS THEREOF | LG CHEM. LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078133-A1 | CATALYST COMPOSITION COMPRISING GROUP 4 TRANSITION METAL COMPLEXES AND METHOD FOR PREPARING POLYOLEFINS USING THE SAME | LG CHEM. LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
| US-5068435-A | Alkylation of amines with alkenes in the presence of alumina catalyst | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1991-11-26 | — | — | US | disclosed |
| US-4967001-A | Adding water to catalyst | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1990-10-30 | — | — | US | disclosed |
| US-4914237-A | REGENERATION OF CATALYSTS BY CONTROLLED ADDITION OF WATER | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1990-04-03 | — | — | US | disclosed |
| US-4876377-A | SELECTIVITY TO ORTHO POSITION, BY-PRODUCT INHIBITION | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4760184-A | Reacting with alcohol, olefin or diolefin in presence of alkylating catalyst of larger microspores | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1988-07-26 | — | — | US | disclosed |
| US-4740620-A | HIGH SELECTIVITY TO THE ORTHO POSITION | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1988-04-26 | — | — | US | disclosed |
| EP-0240018-A2 | Alkylation of aromatic amines with olefins on partially dealuminated zeolites | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | RAB9A 1953/4885NPC1 320/4885SMN1; SMN2 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.